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Abstract
: In this work, we study the consequences of sequence variations of the "2009 H1N1" (swine or
Mexican flu) influenza A virus strain neuraminidase for drug treatment and vaccination. We find that
it is phylogenetically more closely related to European H1N1 swine flu and H5N1 avian flu rather
than to the H1N1 counterparts in the Americas. Homology-based 3D structure modeling reveals
that the novel mutations are preferentially located at the protein surface and do not interfere with
the active site. The latter is the binding cavity for 3 currently used neuraminidase inhibitors:
oseltamivir (Tamiflu®), zanamivir (Relenza®) and peramivir; thus, the drugs should remain effective
for treatment. However, the antigenic regions of the neuraminidase relevant for vaccine
development, serological typing and passive antibody treatment can differ from those of previous
strains and already vary among patients.
Reviewers: This article was reviewed by Sandor Pongor and L. Aravind.
Findings
The recent epidemic of the "2009 H1N1" influenza A
virus (also called swine or Mexican flu) has put the world
on alert since a new swine flu strain (naturally hosted by
pigs) has crossed the species barrier to human and, appar-
ently, acquired the capability for human to human trans-
mission [1,2]. Given earlier experiences with risks of viral
pandemics such as SARS and the avian flu [3], global con-
trol and public health surveillance mechanisms provided
sequences of the new flu strain in public sequence data-
bases within weeks of the outbreak. Here, we analyze the
protein sequence of its neuraminidase with respect to sim-
ilarities and differences to known strains and implications
on drug treatment and vaccination.
Domain architecture and posttranslational modifications
Sequence and residue numbering in this analysis corre-
spond to the neuraminidase [Genbank: ACP41107.1
http://www.ncbi.nlm.nih.gov/protein/227809834] repre-
sentative for the new strain. Sequence analysis was carried
out following an established protocol using the ANNIE
resource [4,5]. The 469 amino acid long neuraminidase
(NA) protein (Figure 1) is essential for release of the viral
particle from the outer membrane of infected cells by
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cleaving sialic acid from host glycoproteins that are recog-
nized by the viral hemagglutinin [6]. As a type II trans-
membrane protein, it is N-terminally attached to the
membrane [7]. It consists of a tiny cytoplasmic tail at the
N-terminus (residues 1 to 6) [8] followed by the trans-
membrane region (residues 7 to 34) that is also responsi-
ble for translocation of the protein [9].
Next, a presumably unstructured linker region (residues
35 to 82) connects the membrane anchor to the catalytic
neuraminidase domain (residues 83 to 469; Figure 1).
Such unstructured linker regions are rich in small and
polar residues and often harbour sites for posttransla-
tional modifications [10,11]. Probable posttranslational
modification sites in the neuraminidase of the new strain
are glycosylation motifs involving N88, N146 and N235,
which correspond to residues that are also glycosylated in
other subtype neuraminidases [12]. However, the mini-
mal and non-specific consensus motif of glycosylation
sites (Nx [ST]) is found in total 8 times in the new strain
sequence with an apparent clustering (50%) in the
unstructured linker region (Figure 1). Interestingly,
another putative novel glycosylation site N386, which is
unique to the new strain, would be accessible on the sur-
face, as seen in the structural models.
Comparing among all strains, the sequence variation is
largest in the linker region, including large deleted seg-
ments. Nevertheless, this region harbours a cysteine (Fig-
ure 2) that can be aligned over multiple NA subtypes and
is conserved in N1-N5 and N8, but not in N6, N7 and N9.
Earlier reports assume that, at least in related viruses,
cysteines in the non-globular region could be involved in
intermolecular disulfide bridges [13-15]. Alternatively, by
analogy to other influenza proteins such as hemaggluti-
nin [16] and M2 protein [17], it cannot yet be excluded
that cysteine C49 is palmitoylated and that the anchor
localizes the protein to lipid rafts [18].
Phylogenetic relation of new NA to known subtypes
Influenza A virus protein sequences were downloaded
from NCBI (as of April 29th). Neuraminidases were iden-
tified by BLAST (E-value < 0.001) [19] using the represent-
ative NA of the new strain as query [Genbank:
ACP41107.1 http://www.ncbi.nlm.nih.gov/protein/
227809834]. Redundancy was removed with cd-hit at a
level of maximal 90% sequence identity [20], the remain-
Domain architecture (drawn with http://au.expasy.org/tools/mydomains/) Figure 1
Domain architecture (drawn with http://au.expasy.org/tools/mydomains/). Besides the labelled domains (TM ... trans-
membrane), grey lollipops indicate known and putative glycosylation sites and the red lollipop marks the conserved cysteine 
shown in Figure 2.
Representative alignment of the sequence environment of the conserved cysteine C49 that could either serve for intermolecu- lar disulfide bridges or as palmitoylation site Figure 2
Representative alignment of the sequence environment of the conserved cysteine C49 that could either serve 
for intermolecular disulfide bridges or as palmitoylation site.Biology Direct 2009, 4:18 http://www.biology-direct.com/content/4/1/18
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ing sequences were aligned with MAFFT (using L-INS-I
settings [21]) and the resulting multiple alignment was
visualized and annotated in Jalview [22]. A neighbour
joining tree with pairwise gap deletion, Poisson correction
as distance measure and 500 bootstrap replicates (gener-
ated with MEGA [23]) produces robust groupings consist-
ent with previous studies [24] for the known NA subtypes
(clustering of N1, N4, N5+N8 on one side and N2, N3,
N6+N7+N9 on the other) and reliably places the new NA
with other N1s. Interestingly, inside the N1 cluster, the
new NA appeared close to the N1 of H5N1 avian flu
viruses. The alignment and corresponding phylogenetic
tree are available at http://mendel.bii.a-star.edu.sg/
SEQUENCES/H1N1/.
Hence, we repeated the analysis (same protocol as out-
lined above) for a detailed mapping of only the N1 sub-
type family with the difference of allowing 95% sequence
identity for sequences before 2009 but keeping all new
NA sequences (as of April 29th). A characteristic clustering
emerges (Figure 3) that roughly corresponds to host and
geographic distributions, consistent with previous reports
[25,26]. The observed clustering is robust in respect to the
method used for tree generation (same for maximum par-
simony or neighbour joining trees with JTT distance and
gamma-distributed variable rates). The 2009 NA is part of
a cluster of avian-like swine flu H1N1 strains predomi-
nantly found in European pigs. However, previous exam-
ples of human infections from swine flu are also part of
the same cluster, for example from 2005 in Thailand [27].
This indicates that, similar to the current outbreak, closely
related H1N1 strains have crossed species boundaries on
previous occasions as also evidenced by further reports in
the literature [28-30].
Moreover, neuroaminidases of these new H1N1 swine flu
examples are more similar to H5N1 avian flu strains than
other H1N1 variants found in the Americas or than that of
the historic strains such as the 1918 Spanish flu [31]. This
is surprising since avian flu strains typically have different
hemaglutinin (HA) subtypes (e.g. H5N1). Combinations
of HA and NA subtypes need to be fine-tuned to recognize
the same type of sialic acid modifications to allow smooth
interplay of the two proteins, which is important for the
viral cycle [6]. These results support the notion that, also
inside the family of N1 subtypes, a clear distinction can be
made between avian-like H1N1, such as the one from the
current outbreak, and other existing H1N1 strains.
Structural modelling and mapping of new mutations
The crystal structures of both the historic 1918 NA as well
as the avian flu NA are available in complex with currently
used drugs. We created a homology model of the new
2009 swine flu NA to map the sequence differences to the
three-dimensional structure templates. Using Modeller
[32], the sequence of the new neuraminidase [Genbank
Accession: ACP41107.1 http://www.ncbi.nlm.nih.gov/
protein/227809834] was modelled 50 times onto multi-
ple templates (PDB: 2hu4[33], 3ckz[34], 3b7e[35],
3beq[35]) and the resulting best model (as judged by
DOPE score) further refined with short simulated anneal-
ing MD simulations in the presence of a bound inhibitor
(zanamivir, oseltamivir or peramivir) as implemented in
the Yasara Structure package [36]. The final atom-resolu-
tion models are available in PDB format at http://men
del.bii.a-star.edu.sg/SEQUENCES/H1N1/.
We mapped the level of residue conservation (calculated
with the evolutionary trace algorithm [37]) from the mul-
tiple alignment of all NA subtypes to its corresponding
position in the structure. The results show the strict con-
servation close to the neuraminidase catalytic site, which
also serves as the drug binding pocket (Figure 4A). The
remaining conserved patches (for example the sites
around N104 or below N146) fit into each other and form
the dimerization/tetramerization interfaces [35]. A model
of the dimeric version is available in PDB format at http:/
/mendel.bii.a-star.edu.sg/SEQUENCES/H1N1/.
Next, we compared the sequences of the new strain with
the related H5N1 from avian flu and H1N1 from the
Spanish flu (Figure 5). Among 387 residues that were
structurally modelled, the "2009 H1N1" neuraminidase
differs from the other two in 21 positions. The mapping
to the structure (Figure 4B) shows that the novel sequence
mutations are distributed all around the surface of the
molecule leaving the hydrophobic core, but also the cata-
lytic site, essentially untouched. Importantly, none of the
new mutations appears sufficiently close to affect the drug
binding pocket. For example, all 17 residues within 3 Å of
the zanamivir molecule bound to the active site are fully
conserved among all three strains. The closest mutation is
the conservative V149I substitution at a distance of ~10 Å
to zanamivir and ~7 Å to oseltavimir.
It has to be noted that indirect effects of the mutations
that may alter the binding pocket also from a greater dis-
tance are difficult to assess and cannot be excluded. To
this extent, we have analysed coevolution patterns in an
extensive alignment of more than 6000 non-identical
Influenza A neuraminidases to eventually identify con-
nected networks of residues using the SCA algorithm [38]
as implemented in [39], but no network that would con-
nect the surface directly to the core and catalytic site was
found (see supplementary material). In fact, all positions
of the observed mutations are at the surface and naturally
variable, as judged by the conservation and SCA analysis,
which would rather indicate that they do not have an
effect on the structure of the more distant binding pocket.
Thus, we conclude that the drug binding pocket remains
unchanged in the new strain and, hence, the bindingBiology Direct 2009, 4:18 http://www.biology-direct.com/content/4/1/18
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Phylogenetic tree of neuraminidase protein sequences of the N1 subtype family Figure 3
Phylogenetic tree of neuraminidase protein sequences of the N1 subtype family.Biology Direct 2009, 4:18 http://www.biology-direct.com/content/4/1/18
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behaviour of neuraminidase inhibitors such as oseltami-
vir (Tamiflu®) and zanamivir (Relenza®) should be unaf-
fected. Indeed, initial clinical reports suggest that the new
virus is susceptible to the two drugs [40]. Our findings
support this notion and provide a molecular mechanism.
Furthermore, the third currently tested neuraminidase
inhibitor, peramivir, should also be effective since it also
shares the same binding pocket.
Next, we review how the new mutations affect vaccine
development through altering antibody interactions as well
as antigenic regions. There are 3 crystal structures of related
neuraminidases in complex with antibodies [41-43]. In
Figure 5, we annotate residues that are within 3 Å distance
to the respective bound antibody and, hence, crucial for the
interaction. Interestingly, residues in sites recognized by
both NC41 and NC10 antibodies appear mutated in the
new strain. This would suggest that these old antibodies
(that were originally directed against N9 neuraminidase)
would probably not bind to NA of the new strain. Never-
theless, using the same regions as epitope may be a viable
option for novel vaccine development.
Additionally, several other known antigenic regions, par-
tially derived from surviving patients of previous flu out-
breaks (e.g. H5N1), are reported in the literature [44-46]
and their location is indicated in the alignment (Figure 5).
Another extensive source of epitopes and antigens includ-
ing neuraminidase of influenza A viruses is the immune
epitope database (IEDB) [47] and the complete mapping
of epitopes for the new H1N1 NA sequence is available at
http://mendel.bii.a-star.edu.sg/SEQUENCES/H1N1/.
While several of the new mutations are found in antigenic
regions, it is also apparent that they often occur on posi-
tions that are hardly conserved among different NA sub-
types. Consequently, these regions are evolutionarily
more flexible and may mutate fast. This increases the risk
of evading antibody responses of human hosts acquired
during previous flu infection or from vaccination.
Sequence variation among patients with the same 2009 
H1N1 strain
After the first wave of new patient sequences arrived, it
becomes clear that there are at least two major lineages
that are distinguishable by only few mutations. Most
notably, N248 has mutated to Aspartate (D248) in the
New York infection cluster. All intra-strain mutations
available before May 8th 2009 are indicated in Figures 4B
and 5. As expected, they are predominantly found on the
surface and in regions that are known to be variable from
the conservation analysis. While the drug binding pocket
remains unaffected by these most recent mutations, the
N248D substitution changes a central part of an antibody
recognition site. This has important consequences for vac-
cine development, forcing to either avoid this epitope or
produce combined vaccines to account for the epitope
A) Surface representation of the structural model of the neuraminidase domain of the new strain in complex with zanamivir Figure 4
A) Surface representation of the structural model of the neuraminidase domain of the new strain in complex 
with zanamivir. Coloring is based on sequence conservation over all NA subtypes. Grey means no conservation. Other 
colors are according to physical properties: yellow ... hydrophobic, green ... polar, blue ... positive charge, red ... negative 
charge. Color intensities are proportional to strength of conservation. B) Mapping of new mutations to structure. Cyan 
colored residues are mutations at typical antibody recognition sites. Blue residues indicate differences to both the H5N1 avian 
flu as well as H1N1 from the 1918 Spanish flu. Yellow residues are intra-strain variations occurring in multiple patients of the 
2009 H1N1 outbreak and orange if they have only been found in isolated patients, so far. Note that the intra-strain variation 
N248D is colored cyan since it is part of the antibody recognition site. The backbone of the antibody recognition sites is 
colored green and the bound drug and 3 calcium ions are shown in red.
B
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Alignment of the NA domain of the 2009 H1N1 strain with the sequences in crystal structures of H5N1 avian flu as well as  H1N1 from the 1918 Spanish flu Figure 5
Alignment of the NA domain of the 2009 H1N1 strain with the sequences in crystal structures of H5N1 avian 
flu as well as H1N1 from the 1918 Spanish flu. Residues within 3 Å of the bound drug are indicated with "#", while resi-
dues that are different in the new strain compared to both other structures are marked with "@".Intra-strain variation (Flex 
[AA] in the first annotation line) is displayed as the respective mutated residue in capital letters if found in multiple patients 
(e.g. D for the N248D substitution) or lower-case (e.g. "i" for V241I) for single occurrences. In the second annotation row, 
antigenic regions are labelled as "*". Residues with < 3 Å contact to antibodies are labelled "A" for interactions derived from 
PDB:1ncb, "B" from both PDB:1ncb and PDB:1nmb, "C" from PDB:1nmb and "D" from PDB:2aep.Biology Direct 2009, 4:18 http://www.biology-direct.com/content/4/1/18
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variation observed in different patient groups. Although
the mutation pattern will become less transparent over
time it may still serve to delineate chains of transmission,
retrospectively.
Conclusion
In summary, we provide a sequence analysis and struc-
tural modelling of the neuraminidase from the 2009
H1N1 swine flu outbreak. Besides mapping of phyloge-
netic relationships to other strains, we find that the
sequence variation in the new strain does not seem to
affect the drug binding site but may very well alter com-
mon epitopes. To allow quick analysis of future mutations
that could produce drug or vaccine-resistant strains, we
provide a tool for 3D visualization of the neuraminidase
structure models with mapping of drug and antibody rec-
ognition sites on the supplementary webpage http://men
del.bii.a-star.edu.sg/SEQUENCES/H1N1/.
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Reviewers' comments
Reviewer 1
Sandor Pongor, International Centre for Genetic Engi-
neering and Biotechnology, Trieste, Italy
In this work, the authors carry out a predictive analysis of the
"2009 H1N1" (swine or Mexican flu) influenza A virus strain,
based on phylogenetic analysis and 3D homology modelling.
The results show that this strain is phylogenetically more closely
related to European H1N1 swine flu and H5N1 avian flu
rather than to the H1N1 counterparts in the Americas.
Homology-modeling of the neuraminidase reveals that the
novel mutations are not likely to interfere with the active site so
the currently used neuraminidase inhibitors (oseltamivir, zan-
amivir and peramivir) will be effective against the new virus
strain.
The subject is very timely and the approach is adequate. The
authors may want to include analysis of more patient data that
were published since the analysis was completed. More and more
sequences are being published from all over the world that might
be worthwhile to include into this analysis. The authors may con-
sider establishing a periodically updated homepage, if appropriate.
In summary, the analysis is careful and carried out in a commend-
able fashion, and the findings are highly significant.
Response
Indeed, there have been additional "2009 H1N1" neu-
raminidase sequences since the submission of this manu-
script for review. Between April 29th and May 8th, 45 new
sequences became available. Overall, 3 mutations occur
in multiple (S95G, V106I and N248D) while 2 mutations
are restricted to single patient virus isolates (V83M,
V241I), so far. We have included a section about these
mutations identified in new patient sequences and
mapped them to the structure. As discussed in the main
text, the intra-strain variation is typically found on the sur-
face and at positions expected to be variable as judged by
the conservation analysis among all NA subtypes. Interest-
ingly, one of the mutations among patients (N248D) is
critically affecting one of the antibody binding sites.
As the virus will continue to evolve, new mutations will
become available and the best way we have found to
allow quick mapping and update of new sequence varia-
tion in respect to drug and antibody binding sites is to give
full access to users/readers via a 3D structure visualization
tool at the supplementary webpage http://mendel.bii.a-
star.edu.sg/SEQUENCES/H1N1/ (instructions to map
new mutations are given, including an example).
Reviewer 2
L. Aravind, National Center for Biotechnology Informa-
tion, Bethesda, MD, USA
Maurer-Stroh et al discuss sequence features of the neuraminidase
gene of the virus behind the latest influenza outbreak, 2009
H1N1. Of the features of interest they note that this strain has
acquired a novel glycosylation consensus site that could be surface
accessible. Of course, it remains unknown if this site is indeed used
for modification. The key finding in the paper is that the binding
cavity for neuraminidase inhibitors is unaffected as suggested by
molecular modeling. This finding is of significance in the current
situation of an outbreak with pandemic potential. However, one
issue needs to be highlighted in this regard – mutations far away
from the binding site can potentially affect the shape and or bind-
ing affinity of the binding pocket. These are not always captured by
homology models, especially the issue of affinity. In principle,
authors could use a conservation patterns or co-evolution measures
(e.g. as in PMID: 10514373) to determine if there are interaction
chains that might connect distant residues to the active site. In the
least it would be useful to provide the caveat of distant changes
affecting affinity in the current paper.
Response
We totally agree with the referee that also mutations at a
greater distance may affect the binding pocket under spe-Biology Direct 2009, 4:18 http://www.biology-direct.com/content/4/1/18
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cial circumstances and we have added a new paragraph to
the manuscript. However, we have to admit that it
remains essentially impossible to quantify the influence
of non-direct interactions by theoretical means unambig-
uously. In our experience, co-evolution measures such as
the one proposed and several others (PMID: 18056067)
produce high rates of false positives and, therefore, the
interpretation is difficult. We did the requested analysis
with Ranganathan's SCA algorithm to eventually identify
connected networks of residues using the webserver
implementation at the Gerstein lab, but no network that
would connect the surface directly to the core and catalytic
site was found (see supplementary webpage for full
details). In fact, all positions of the observed mutations
are at the surface and naturally variable, as judged by the
conservation and SCA analysis, which would rather indi-
cate that they do not have an effect on the structure of the
more distant binding pocket. A possible problem why the
SCA could not work in this case is the high level of
sequence similarity among the neuraminidases which
only gives limited numbers of informative correlated
mutations. This is a totally different scenario from align-
ments of highly divergent sequences that still have the
same fold, such as the small PDZ domains analyzed by
Ranganathan. In the case of a diverse family with shared
fold, correlated mutations are indicative of allowed fluc-
tuations also among structurally important residues.
However, with the neuraminidases, most variation can be
attributed to surface residues, which makes sense given
the pressure to avoid immune responses. Additionally,
sequence sampling of neuraminidases is not independent
but biased by transmission chains and clusters of out-
breaks. A possible but also not necessarily more precise
alternative to judge indirect effects on drug binding would
be to run free energy simulations with the bound drug to
judge changes of affinity caused by the mutations but this
is a tricky and time-consuming endeavour that would
burst the scope of this current manuscript.
unspecific consensus motif: change to "non-specific"
Response
changed.
Phylogenetic analysis: While for sequences at this range of similar-
ity Poisson correction may not have negative consequences it is def-
initely better to repeat the analysis with JTT and variable rates to
see if the clustering remains the same or changes drastically.
Response
We confirmed that the tree clustering inside the N1 sub-
type family is robust regarding different tree generation
methods and added this also to the text. We also provide
the suggested JTT distance tree with variable rates as sup-
plementary at http://mendel.bii.a-star.edu.sg/
SEQUENCES/H1N1/.
" This indicates that, similar to the current outbreak, scenarios of
breaches in the species barrier between human and pigs have
already arisen out of closely related H1N1 strains as also evidenced
by further reports in the literature [26,27]." The wording of this
sentence is somewhat unclear. It appears that the authors wish to
state that H1N1 like strains have crossed species boundaries on
other occasions, but this is not necessarily clear in the sentence.
Response
changed to "This indicates that, similar to the current out-
break, closely related H1N1 strains have crossed species
boundaries on previous occasions as also evidenced by
further reports in the literature".
"These results support the notion that, also inside the family of
N1 subtypes, a clear distinction can be made to distinguish
avian-like H1N1, such as the one from the current outbreak,
from other existing H1N1 strains." What would be the expla-
nation for this? A recent recombination between an avian-like
H1N1 or has it diverged from other avian like H1N1 with the
recombination occurring much earlier. Could this information
be superimposed in phylogenetic context on current figure 3?
Response
This is, of course, a very interesting question and difficult
to deduce from the phylogenetic tree of a single protein
without molecular clock, as in our case. However, this and
similar questions have already been analyzed to quite
some detail for the existing strains. The current knowledge
of the scenario for H1N1 is that around the late 1970s to
early 1980s, a human-avian reassortant virus started to be
detected in European pigs as host (PMID: 8091678).
Then, this avian-like swine flu started to move from the
European continent to the UK in the early 90s (PMID:
9049404). More reassortments and emergence of the N2
subtype that quickly spread is also well documented. This
phylogenetic analysis plugs the new H1N1 strain into the
already known clusterings among the NA subtypes and
within the N1 family.
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